We use cookies to make it easier for you to use our website and give you a better experience. We aggregate the information we get through cookies from users like you, and analyze that data to better understand user behavior and help us improve the website. We do not give or sell the data you provide through cookies to any third party for any purpose (such as advertising or marketing). By using this website, you consent to Organogenesis using cookies for these purposes. You may change your settings anytime by clicking on the “Security” tab on your browser. Note that Organogenesis is located in the United States, and the U.S. has not yet been determined to have “adequate” data privacy safeguards by the EU; despite any inherent risks in the transfer of data from the EU, Organogenesis takes the security of your information seriously. To read our privacy policy, click here.

Diabetic Foot Ulcer

Significantly more effective than conventional therapy

Incidence (%) of Complete Wound Closure Over Time (N=208)*

By 12 weeks of treatment, 56% (63/112) of diabetic foot ulcers treated with Apligraf plus conventional therapy (debridement, saline dressings, total off-loading) were 100% closed, compared to 39% (36/96) of ulcers treated with conventional therapy alone (P=.0026).

Apligraf is indicated for use with standard therapeutic compression for the treatment of noninfected partial-and full-thickness skin ulcers due to venous insufficiency of duration greater than 1 month that have not adequately responded to conventional ulcer therapy. Apligraf is also indicated for use with standard diabetic foot ulcer care for the treatment of full-thickness neuropathic diabetic foot ulcers of greater than 3 weeks duration that have not adequately responded to conventional ulcer therapy and that extend through the dermis but without tendon, muscle, capsule, or bone exposure.

*Estimated frequency of complete diabetic foot ulcer wound closure as a function of time by Kaplan-Meier analysis. Download complete prescribing information.

Proven to Promote Rapid Closure of Diabetic Foot Ulcers

Median Time to 100% Wound Closure

The median time to 100% wound closure was 65 days for diabetic foot ulcers treated with Apligraf plus conventional therapy vs 90 days for ulcers treated with conventional therapy alone (P=.0026).

92% of ulcers remain closed with Apligraf

At 6 months after the initiation of therapy, the incidence of ulcer recurrence was 8% (5/63) in the Apligraf group and 17% (6/36) in the control group. (These results are not statistically different) Download complete prescribing information.

Apligraf – Lower Incidence of Osteomyelitis and Frequency of Amputation

Patients receiving Apligraf had a statistically significant (P<.05) lower incidence of osteomyelitis at the study ulcer site (2.7% vs 10.4%) compared to patients treated with conventional therapy at 6 months. (These data compare with 8.9% and 3.1%, respectively, at sites other than the study ulcer).

  • All patients were screened at baseline and underwent x-ray evaluation for clinical signs of infection
  • Osteomyelitis may be associated with a higher frequency of amputation in patients with diabetic foot ulcers1

Apligraf-treated patients required significantly fewer amputations/resections of the study limb (6.3% vs 15.6%) [P <.05] compared to patients treated with conventional therapy at 6 months.

References:
1. Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999;22:382-387.